Last updated: February 20, 2026
Who are the leading manufacturers and suppliers?
Multiple pharmaceutical companies globally produce or distribute darifenacin hydrobromide, primarily as an active pharmaceutical ingredient (API). The supply chain includes both large drug manufacturers and specialized API producers.
Major API Suppliers
| Supplier |
Location |
Capabilities |
Certification |
Notes |
| Zhejiang Medicine Co., Ltd. |
China |
API production, OEM services |
GMP |
Supplies to global generic firms |
| Jiangsu Hengrui Medicine Co., Ltd. |
China |
API manufacturing |
GMP |
Large scale, diversified portfolio |
| Jiangsu Nhwa Pharmaceutical Co., Ltd. |
China |
API production, R&D |
GMP |
Focused on CNS and urology drugs |
| Afrigen Biologics & Vaccines |
South Africa |
API production and formulation |
WHO GMP |
Expanding API portfolio |
| PDL BioPharma |
US |
API supply, licensing |
cGMP |
Provides APIs for research use |
Key Pharmaceutical Companies Distributing Darifenacin
| Distributor |
Regions Served |
Notes |
| Sun Pharmaceutical Industries Ltd. |
Global, especially South Asia and Africa |
Offers finished drug formulations; source varies by region |
| Teva Pharmaceutical Industries Ltd. |
Global |
Provides generic darifenacin as part of Urology portfolio |
| Mylan (now part of Viatris) |
Worldwide |
Supplies generic formulations, procurement from multiple API suppliers |
| Sandoz (Novartis) |
US, Europe |
Generic formulations, API sourced internationally |
Regulatory and Certification Standards
- GMP (Good Manufacturing Practice): API suppliers and finished product manufacturers must adhere to GMP standards issued by authorities such as the FDA (US), EMA (Europe), or equivalent local regulators.
- ISO Certifications: Many suppliers have ISO 9001 certifications for quality management systems.
- Additional Certifications: Some suppliers seek WHO GMP or PIC/S compliance to ease international distribution.
Regional Dynamics
- China remains the primary source for bulk APIs, accounting for over 90% of global API manufacturing capacity, including darifenacin hydrobromide.
- U.S. and European suppliers predominantly focus on finished formulations due to tighter regulations and the need for higher quality assurance standards.
- Distribution networks are well-established with licensing, import/export approvals, and supply agreements.
Supply Chain Risks and Considerations
- API production concentrated heavily in China presents risks of supply disruption due to geopolitical, regulatory, or pandemic-related factors.
- Quality assurance varies by supplier; due diligence is necessary before entering supply agreements.
- Regulatory approvals for APIs differ by region, affecting the ability to sell finished products internationally.
Market Facts
- Global darifenacin hydrochloride sales are projected to grow at a CAGR of 3-4% over the next five years.
- Patent expiration for darifenacin extended its generic manufacture, increasing supply options.
- Larger pharmaceutical companies favor established API suppliers for compliance and reliability.
Conclusion
The principal API suppliers for darifenacin hydrobromide are primarily based in China, with key distributors offering finished formulations globally, including Teva, Mylan, and Sun Pharma. Supply reliability hinges on quality standards, regional regulations, and geopolitical stability.
Key Takeaways
- Chinese API manufacturers dominate the supply of darifenacin hydrobromide.
- Major generic drug producers source APIs from multiple suppliers to mitigate risk.
- Regulatory compliance (GMP, ISO) is critical in selecting suppliers.
- Market expansion relies on diversified supply chains with reliable supply and quality assurance.
- Geographic concentration in API manufacturing poses potential supply risks.
FAQs
1. Who are the largest API producers for darifenacin hydrobromide?
Chinese companies Zhejiang Medicine, Jiangsu Hengrui, and Jiangsu Nhwa lead API manufacturing, with others expanding capacity globally.
2. Are there regional differences in supplier quality for darifenacin?
Yes. Chinese APIs generally supply bulk, with variable quality assurance; regulated markets prefer suppliers with certified GMP and ISO standards.
3. Can I source darifenacin hydrobromide directly from API suppliers?
Typically, only licensed drug manufacturers obtain APIs directly. Distributors and pharmaceutical companies purchase finished formulations.
4. What risks are associated with relying on Chinese API suppliers?
Potential risks include supply disruptions, regulatory non-compliance, or quality issues. Diversifying sources mitigates these risks.
5. How does patent status influence supply options for darifenacin?
Patent expirations have enabled generic manufacturers to enter the market, increasing supply options and competition among API and finished product suppliers.
References
- U.S. Food and Drug Administration. (2022). Guidance for Industry: Good Manufacturing Practice Regulations.
- European Medicines Agency. (2021). Guidelines on good manufacturing practice.
- MarketsandMarkets. (2022). Urology Drugs Market Report.
- China Pharmaceutical Industry Association. (2021). Chinese API manufacturing capacity overview.
- Novartis. (2023). Sandoz Product Portfolio.
